Trial Profile
A phase II study of the Cladribine and Rituximab combination therapy for relapsed and refractory indolent B-cell Non-Hodgkin's Lymphoma.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2008
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 18 Dec 2008 New trial record.